|
Sahajanand Medical Technologies Opens
New R&D Facility In Ireland
Sahajanand Medical Technologies Pvt. Ltd.(SMT), India’s
largest manufacturer of cardiovascular medical stents, has announced the opening
of its new research & Development Centre in Galway City, Ireland. SMT aims to
attract global talent through this new facility in Ireland to diversify its
product portfolio.
The company has significant investment plans to develop this
R&D Centre. The core functions of SMT Ireland Centre would be R&D and logistics.
The key on-going research projects at the facility are developing next
generation of Stent and Advanced Balloon Catheter technology. The centre will
have detailed and advanced research on developing next generation stent. It will
be working on advanced balloon catheter and stent bifurcation application which
will be a great help in complex cases. The centre will also be flexible from
logistics point of view as it will be able to track and deliver the stents and
other products in various parts of the world.
The Ireland centre also plans to develop new range of
peripheral products along with guidewires and other coronary accessories. The R&D
leadership team is in place now and more researchers are expected to join the
team in the coming weeks.
Commenting on the launch, Ganesh Sabat, CEO of SMT, said, “We
were pioneers amongst Indian medical device companies and have seen tremendous
value in investing in research & development (R&D). Our early investments in
R&D, beginning one and half decades ago, enabled us to make technology our key
differentiator and develop a robust coronary stent for the world. Our core
strength lies in our ability to excel in developing technologically complex
products through focused teams.”
The launch of the centre was attended by Sean Kyne, Minister
of State, and Noel Larkin, Mayor of Galway City.
This is a major investment by SMT to remain ahead of the
curve in adopting latest technologies through advanced research and compete with
global competitors. Our aim is to continue to provide the most advanced
technology to our consumers at competitive prices hence aligning with our vision
of ‘pledge to save millions’. With this centre, we hope to tap into the global
talent pool and explore the possible adaptation into the Indian market and
strengthen India as a medical device manufacturing hub. This will provide a big
fillip to support our Prime Minister’s dream of Make in India in the medical
device industry, said Sabat.
Established in the year 1998, SMT became the first indigenous
player in India to successfully launch coronary stent. SMT is also the first
company to get CE approval for DES with Biodegradable Polymers in the world. It
is India’s largest stent manufacturing company and sells its product in more
than 60 countries across the world.
(Ref:
http://www.pharmabiz.com/NewsDetails.aspx?aid=97809&sid=2)
|
